Recent Advances in the Production of Mammalian-Type Sugar Chains in Yeast
Protein therapeutics, such as enzyme replacement therapy, antibody therapeutics, and cytokine administration, are now known as the largest class of new candidates developed by the pharmaceutical companies. Yeasts have been used to produce industrial enzymes and are often chosen as the expression system because manufacturing costs are of primary concern. However, yeasts have a drawback of inability to attach mammalian-type sugar chain for the production of therapeutic glycoproteins for human use. N-glycosylated sugar chain in yeast is a mannan-type, which is partly antigenic in human and is sometimes trapped and cleared by mannose-specific receptors or lectins. Over the past 15 years or so, several approaches have been attempted to substitute yeast glycosylation pathway for a human one, and recently, many advances in the expression of therapeutic glycoproteins with mammalian-type sugar chains in yeast have been demonstrated.
KeywordsEnzyme Replacement Therapy Fabry Disease Sugar Chain Mannose Residue Epidermal Growth Factor Domain
Unable to display preview. Download preview PDF.
- Chigira Y, Oka T, Okajima T, Jigami Y (2008) Engineering of a mammalian O-glycosylation pathway in the yeast Saccharomyces cerevisise: production of O-fucosylated epidermal growth factor domains Glycobiology, in press, doi:10.1093/glycob/cwn008Google Scholar
- Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S, Bobrowicz P, Stadheim TA, Li H, Choi BK, Hopkins D, Wischnewski H, Roser J, Mitchell T, Strawbridge RR, Hoopes J, Wildt S, Gerngross TU (2006) Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313:1441–1443PubMedCrossRefGoogle Scholar